Submissions from 2022
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study, Vadim S. Koshkin, Guru P. Sonpavde, false Hwang, Begona Mellado, Gareth Tomlinson, Masashi Shimura, Michael J. Chisamore, Maciej Gil, and Yohann Loriot
OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis, A. Kulkarni, C. Hennessy, G. Wislon, V. Ramesh, Clara Hwang, A. Joy, Z. Bakouny, H. Khan, D. Vilar-Compte, R. McKay, C. Jani, J. W. Riess, M. Puc, A. Kasi, S. Berg, D. R. Castillo, B. Hayes-Lattin, W. Hosmer, D. Flora, S. Mishra, B. French, J. Warner, G. Lopes, S. Peters, and N. Duma
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. S. Hong, R. Shazer, X. Yan, L. Latven, and K. He
A CASE OF T-CELL PROLYMPHOCYTIC LEUKEMIA PRESENTING WITH VAGINAL BLEEDING, Zeinab Nasser, Aula Ramo, and Vrushali Dabak
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results, Nitin Ohri, Shruti Jolly, Benjamin T. Cooper, Rafi Kabarriti, William R. Bodner, Jonathan Klein, Shankar Viswanathan, Elaine Shum, Joshua K. Sabari, Haiying Cheng, Rasim A. Gucalp, Enrico Castellucci, Angel Qin, Shirish M. Gadgeel, and Balazs Halmos
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT), N. Ohri, S. Jolly, B. T. Cooper, R. Kabarriti, W. R. Bodner III, J. Klein, S. Viswanathan, R. Kaufman, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
RACIAL ETHNIC DIFFERENCES IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS: ANALYSIS OF A LARGE REAL-WORLD DATASET, Laura Oswald, L. Robert Gore, Melanie Buhlmann, Naomi Brownstein, Kea Turner, Andreas Saltos, Jhanelle Gray, Shirish M. Gadgeel, Clement Gwede, Susan Vadaparampil, Brian Gonzalez, and Heather Jim
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST), Solange Peters, Shirish M. Gadgeel, Tony S. K. Mok, Ernest Nadal, Saadettin Kilickap, Maurice Perol, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Mor Moskovitz, Chong-Jen Yu, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay N. S. Bhagawati Prasad, Venice R. Archer, and Rafal Dziadziuszko
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/ metastatic NSCLC from the Blood First Assay Screening Trial (BFAST), Solange Peters, Shirish M. Gadgeel, Tony S. K Mok, Ernest Nadal, Saadettin Kilickap, Maurice Perol, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Mor Moskovitz, Chong-Jen Yu, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay N. S Bhagawati Prasad, Venice R. Archer, and Rafal Dziadziuszko
Financial impact of immunotherapy-related adverse events among inpatient admissions with solid malignancies, Rayli Pichardo, Yazan A. Omar, and Ding Wang
Inpatient complications of immunotherapy-associated colitis in solid malignancies: Real-world data analysis, Rayli Pichardo, Yazan A. Omar, and Ding Wang
Race-specific genomic determinants of therapeutic response in African American NSCLC patients, Amanda Pilling, Pin Li, Kaitlyn Kane, Frank M. Wolf, Anna B. Berry, and Shirish M. Gadgeel
Sentinel Lymph Node Positivity in Clinically Node Negative Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunities to Defer Intraoperative Frozen Section Analysis, Omar Qutob, Jessica Bensenhaver, Laura L. Susick, Lindsay Petersen, Anna Lehrberg, Fallon Dimaano, and Theresa Schwartz
Is smoking prognostic for advanced metastatic pancreatic cancer (PC) patients undergoing treatment, Aula Ramo, Zeinab Nasser, Mohamad Beidoun, Baha' M. Abbad, Nayef H. Abdel-Razeq, and Gazala Khan
Disparity Outcomes in Patients Undergoing Pancreas Surgery at an Urban Tertiary Care Center, Mariam A. Saad, Kendyll J. Gartrelle, Rupen Shah, Julie Clark, Kyra Langley, Erin Field, Christopher P. Steffes, and David S. Kwon
A single-center analysis of 30- and 90-day post-pancreatectomy complications in patients undergoing neoadjuvant radiation with EBRT versus MRI-guided SBRT, Mariam Saad, Julie Clark, Rupen A. Shah, Farzan Siddiqui, Parag J. Parikh, Kendyll J. Gartrelle, Abdul Kader Natour, Gazala Khan, and David Kwon
Evaluation of Practice Patterns and Outcomes after Implementing SMART for Pancreatic Cancer, Eric Schaff, Parag J. Parikh, Pin Li, Rupen Shah, Gazala Khan, Farzan Siddiqui, Benjamin Movsas, and David Kwon
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC), Alexander I. Spira, David R. Spigel, D. Ross Camidge, Adrianus De Langen, Tae Min Kim, Koichi Goto, Yasir Y. Elamin, Elaine Shum, Karen L. Reckamp, Julia K. Rotow, Sarah B. Goldberg, Shirish M. Gadgeel, Ticiana Leal, Faris Albayya, Sarah Fitzpatrick, Melinda Louie-Gao, Jagan Parepally, Alena Zalutskaya, and Helena A. Yu
Update on a pilot study: Flumeltbi peripheral blood HLAhaploidentical stem cell transplantation with post-transplant cyclophosphamide and bortezomib (Cy2Bor3), Sowjanya Vuyyala, Edward Peres, Klodiana Neme, Nancy Mikulandric, Susan M. Wautelet, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Scott R. Rohrer, Elizabeth A. Henne, Sarah Szymanski, Josephine Emole, Muneer H. Abidi, and Shatha Farhan
Post-acute sequelae of SARS-CoV-2 infection in patients with cancer, Jeremy L. Warner, David J. Pinato, Sanjay Mishra, Renee M. Saliby, Clara Hwang, Shuchi Gulati, Rana R. McKay, Chris Labaki, Elizabeth A. Griffiths, Chinmay Jani, Peter P. Yu, Andrew J. Portuguese, Matthew Puc, Pamela Egan, Sumit Shah, Anup Kasi, Stephanie A. Berg, Daniel B. Flora, Melissa K. Accordino, and Dimpy P. Shah
IMMUNOTHERAPY INDUCED MYOCARDITIS, Aseel Yaseen and Randa Loutfi
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts), Zeynep B. Zengin, Nicholas Henderson, Joseph J. Park, Alicia Ali, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Laura Graham, Deepak Kilari, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Michael T. Schweizer, Andrew J. Armstrong, Rana R. McKay, Ajjai S. Alva, and Tanya B. Dorff
Submissions from 2021
Satisfaction of hem/onc patients with video visits during the COVID-19 pandemic at a tertiary care center in Michigan, Fawzi Abu Rous, Pin Li, Mohamed Elgamal, Hussna Abunafessa, Rebecca Chacko, Sowjanya Vuyyala, Yaser Alkhatib, and Philip Kuriakose
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup, J. Ajani, F. El Hajbi, D. Cunningham, M. Alsina, P. Thuss-Patience, G. Scagliotti, M. Van den Eynde, Igor Rybkin, L. Shen, K. Kato, S. Kim, S. D'Alonzo, W. Yu, A. Tao, and E. Van Cutsem
1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy, Nino Balanchivadze, Zeinab Nasser, Muhammad Shahid, Cortney McKay, Pin Li, Ryann Sohaney, and Shirish M. Gadgeel
P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors, L. Bazhenova, N. Girard, A. Minchom, S. Ou, Shirish M. Gadgeel, J. M. Trigo, S. Viteri, A. Londhe, P. Mahadevia, and J. Bauml
A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIb/Iv nonsmall cell lung cancer (NSCLC): The landscape 1011 trial in progress, Michael Boyer, Sandip Patel, Thomas Marron, Nick Pavlakis, Sagun Parakh, Shirish Gadgeel, Michael Shafique, Robert Hoyer, D. Ross Camidge, Charles Farber, Ranee Mehra, Tarek Mekhail, Prunella Blinman, Karey Kowalski, Craig Davis, Dmitri Pavlov, Nayra Gad, and Erminia Massarelli
Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis, Francesca Coutinho, Zartash Gul, Anna B. Berry, Michael A. Thompson, Christopher A. Willner, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Jeanna Wallenta Law, Frank M. Wolf, Thomas D. Brown, and Philip Kuriakose
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C, R. Dziadziuszko, S. Peters, Shirish M. Gadgeel, S. M. Shagan, E. Felip, A. Morabito, P. Cheema, M. C. Dols, Z. Andric, C. H. Barrios, M. Yamaguchi, E. Dansin, P. Danchaivijitr, M. Johnson, S. Novello, D. R. Gandara, E. Schleifman, J. Wang, and T. S.K. Mok
1632P At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience, T. Esakia, T. Melkadze, K. Tsiklauri, E. Mariamidze, S. Tsitsilashvili, N. Otkhozoria, M. Abuladze, N. Jokhadze, and Nino Balanchivadze
Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189, Shirish Gadgeel, Jhanelle Grey, Maria Teresa Rizzo, Patrick Peterson, Jongseok Kim, and Delvys Rodríguez-Abreu
P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors, Shirish M. Gadgeel, M. Izano, C. Sweetnam, Igor Rybkin, M. Hendawi, J. Weese, A. Patel, D. Reding, J. Treisman, A. Stafford, F. Wolf, C. Zhang, and T. Brown
MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC), J. F. Gainor, G. Curigliano, D. W. Kim, D. H. Lee, B. Besse, C. S. Baik, R. C. Doebele, P. Cassier, G. Lopes, D. SW Tan, E. Garralda, L. Paz-Ares, B. C. Cho, Shirish M. Gadgeel, M. Thomas, S. V. Liu, C. Clifford, H. Zhang, C. D. Turner, and V. Subbiah
KRAS mutations in patients with nonsquamous non-small-cell lung cancer: Prevalence and relationship with PD-l1 expression, tumor mutation burden and smoking status, Marina C. Garassino, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Dariusz M. Kowalski, Kazuo Kasahara, Enriqueta Felip, Yi-Long Wu, Gilberto de Castro, Byoung Chul Cho, Hande Z. Turna, Hidehito Horinouchi, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Tony S. K Mok, Gilberto Lopes, Julie Kobie, Yongjin Li, Mark A. Ayers, Razvan Cristescu, Bin Zhao, M. Catherine Pietanza, and Roy S. Herbst
MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations, N. Girard, L. Bazhenova, A. Minchom, S. Ou, Shirish M. Gadgeel, J. Trigo, S. Viteri, G. Li, P. Mahadevia, A. Londhe, D. Backenroth, T. Li, and J. M. Bauml
61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199, J. N. Graff, S. Tagawa, C. Hoimes, W. Gerritsen, U. N. Vaishampayan, T. Elliott, Clara Hwang, A. J.T. Tije, A. G. Omlin, R. S. McDermott, R. De Wit, P. Qiu, C. Poehlein, J. Kim, L. Suttner, R. Cristescu, M. J. Marton, C. Schloss, J. S. de Bono, and E. S. Antonarakis
Phase 1 trial of SQ3370 in solid tumors, Alexander Guminski, Ding Wang, Nam Bui, Vivek Bhadri, Madhawa De Silva, Robert Steffner, Nathan A. Yee, Sangeetha Srinivasan, Jose M. Mejia Oneto, M. Wayne Saville, and Vivek Subbiah
Creating PDXs from continental African breast tumors: Addressing racial inequity through science, Evelyn M. Jiagge, Tahra K. Suhan, Jessica M. Bensenhaver, Michele Dziubinski, Joseph K. Oppong, Francis Aitpillah, Awuah Baffour, John D. Carpten, Lisa A. Newman, Sofia D. Merajver, and Max S. Wicha
P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis, Leila Khaddour, C. Zhang, Faria Ali, Shirish M. Gadgeel, E. Tadesse, M. Thompson, D. Reding, J. Treisman, A. Berry, M. Izano, C. Sweetnam, A. Stafford, F. Wolf, T. Brown, and Igor Rybkin
A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies, Tae Min Kim, Dok Hyun Yoon, Ahmad Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, and Seok Jin Kim
Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/ activation in patients with microsatellitestable/ instability-low metastatic colorectal cancer in a phase 1 study, David Krige, Marwan Fakih, Lee Rosen, Ding Wang, Wael Harb, Hani Babiker, Jordan Berlin, Gianfranco Di Genova, David Miles, Mark Powell, Minesh Patel, Jo Carter, Richard Brown, and Tom Lillie
CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma, O. Lawal, O. Lupak, I. Udo, and Josephine Emole
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. R. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. Hong, R. Shazer, X. Yan, L. Latven, and K. He
Phase 1 study of mRNA-2752, A lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36G, for intratumoral (ITU) injection +/-durvalumab in advanced solid tumors and lymphoma, Manish Patel, Antonio Jimeno, Ding Wang, Salomon Stemmer, Todd Bauer, Randy Sweis, Ravit Geva, Shivaani Kummar, Patrick Reagan, Ruth Perets, Patricia LoRusso, Shilpa Gupta, Sima Zacharek, Andressa Laino, Oleg Milberg, Josh Frederick, Sheryl Chen, Stephanie Pascarella, William Randolph, Praveen Aanur, Lisa Johansen, Khanh Do, Robert Meehan, and Ryan Sullivan
961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers, M. R. Posner, A. L. Ho, J. Niu, L. Nabell, R. S. Leidner, J. Nieva, D. L. Richardson, A. T. Pearson, Ding Wang, K. Chung, D. R. Adkins, A. Pimentel, S. Wong, C. Lacobucci, X. Qing, K. Katchar, K. Schlienger, I. Matushansky, S. Fu, and D. G. Pfister
KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation, G. J. Riely, S. H.I. Ou, Igor Rybkin, A. Spira, K. Papadopoulos, J. K. Sabari, M. Johnson, R. S. Heist, L. Bazhenova, M. Barve, J. M. Pacheco, K. Velastegui, C. Cilliers, P. Olson, J. G. Christensen, T. Kheoh, R. C. Chao, and P. A. Janne
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, and Ecaterina I. Dumbrava
Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, M. R. Sharma, R. D. Carvajal, G. J. Hanna, Y. K. Kang, J. Lee, K. W. Lee, B. T. Li, K. N. Moore, M. Pegram, D. Rasco, A. Spira, Ding Wang, B. A. Weinberg, M. Alonso, L. Fang, A. Husain, M. Kowanetz, E. A. Perez, and E. I. Dumbrava
OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers, M. Smeltzer, B. Bunn, Y. S. Choi, L. Coate, J. Corona-Cruz, A. Drilon, N. Duma, M. Edelman, M. J. Fidler, Shirish M. Gadgeel, Y. Goto, R. Herbst, M. Hesdorffer, K. Higgins, B. Labdi, T. Leal, S. Liu, J. Mazotti, S. Novello, S. Patel, S. Popat, R. Ramirez, K. Reckamp, N. Reguart, R. Soo, A. Tan, J. Wolf, S. Yano, B. Stiles, and A. Baird
P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors, D. R. Spigel, D. Rodríguez-Abreu, F. Cappuzzo, V. Velcheti, A. K. Ganti, D. Johnson, R. Govindan, S. Antonia, B. Besse, M. Altan, M. Edelman, S. Ramalingam, E. Felip, Shirish M. Gadgeel, O. Juan-Vidal, A. Gupta, S. Currie, W. Lin, M. Tagliaferri, and M. Reck
MO01.33 CRESTONE – Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210), D. Spigel, S. N. Waqar, M. E. Burkard, J. J. Lin, Y. K. Chae, M. A. Socinski, Shirish M. Gadgeel, K. L. Reckamp, S. M. Leland, D. Plessinger, L. Kunkel, J. R. Bauman, G. Otterson, B. Halmos, Ou SH Ignatius, T. Patil, Y. Y. Elamin, and E. S. Kim
Hyperhemolysis Syndrome in SCD Patient: Reminder of a Rare but Life-Threatening Complication of Blood Transfusion, Aroob Sweidan, Sowjanya Vuyyala, Peter Xie, Mohammad Alhyari, Vrushali Dabak, and Zaher K. Otrock
LUMINOS-102: PVSRIPO with or without immune checkpoint blockade in unresectable anti-PD-1 refractory melanoma, Ding Wang, C. Lance Cowey, Evan Pisick, John Kirkwood, Daniel Corum, Shannon R. Morris, Andrea T. Kelly, Jessica Sorrentino, Lori Mixson, Adam Dickinson, W. Garrett Nichols, and Yana G. Najjar
P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome, C. Wood, G. Lopez, L. Zhao, M. Li, N. Surya, S. Patel, M. Grogan, E. Bertino, P. Shields, K. He, D. Carbone, G. Otterson, C. Presley, B. Pannecouk, G. Kalemkerian, B. Schneider, Shirish M. Gadgeel, N. Ramnath, D. Owen, and A. Qin
Submissions from 2020
A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours, M. A. Carducci, Ding Wang, C. Habermehl, M. Bödding, F. Rohdich, S. Stinchi, O. Karpenko, C. Gimmi, and P. LoRusso
Towards Evidence Based Practice: The American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Guidelines on Radiation Therapy for Muscle-Invasive Bladder Cancer, T. K. Dinh, T. Mitin, K. Hoffman, Clara Hwang, R. J. Karnes, A. Kishan, S. Liauw, S. Lloyd, L. Potters, T. Showalter, A. Taira, N. Vapiwala, N. Zaorsky, A. D'Amico, P. Nguyen, and B. Davis
Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD), R. Dziadziuszko, Q. Zhang, X. Li, S. M. Paul, M. Sugidono, S. Mocci, A. Kinkolykh, D. S. Shames, V. Archer, M. S. Mathisen, D. X. Jin, Shirish M. Gadgeel, S. Peters, and T. Mok
Prospective Randomized Study of Prophylactic Ciprofloxacin Versus Levofloxacin in Hematopoietic Stem Cell Transplant Patients: An Interim Report, Shatha Farhan, Georgiana Marusca, Michael Bazydlo, Klodiana Neme, Nancy Mikulandric, Josena K. Stephen, Nada Kortam, Mayur Ramesh, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Elizabeth A. Henne, Scott R. Rohrer, Sarah Szymanski, Josephine Emole, Edward Peres, and Nalini Janakiraman
Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses, Shirish M. Gadgeel, M. Yan, S. M. Paul, M. Mathisen, S. Mocci, Z. J. Assaf, R. Patel, E. S. Sokol, T. Mok, S. Peters, L. Paz-Ares, and R. Dziadziuszko
Racial Disparities Among Pancreatic Adenocarcinoma Patients: A Retrospective Survival Analysis of Non-Metastatic Pancreatic Cancer Patients, Kendyll J. Gartrelle, Eric M. Schaff, Celina Kirsch, David Kwon, Munther Ajlouni, Gazala Khan, Rupen Shah, Irina Dobrosotskaya, Parag J. Parikh, and Farzan Siddiqui
Does Age Impact Outcomes of Oropharyngeal squamous cell carcinoma?, Ahmed I. Ghanem, Matthew Schymick, Souheyla Bachiri, Remonda M. Khalil, Charlotte Burmeister, Jawad Sheqwara, Steven S. Chang, Tamer Ghanem, and Farzan Siddiqui
Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5, J. N. Graff, E. S. Antonarakis, C. J. Hoimes, S. T. Tagawa, Clara Hwang, D. Kilari, A. J. Ten Tije, A. G. Omlin, R. S. McDermott, U. N. Vaishampayan, A. Elliott, H. Wu, J. Kim, C. Schloss, and J. S. De Bono
Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate, E. P. Hamilton, M. A. Barve, A. W. Tolcher, J. Buscema, K. P. Papadopoulos, C. Zarwan, C. K. Anderson, D. Doroshow, Ding Wang, D. Huebner, V. M. Jansen, D. Jarlenski, R. Mosher, J. Kaufman, K. N. Moore, and D. L. Richardson
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC, Kristin A. Higgins, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George B. Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, and Joe Y. Chang
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation, P. A. Jänne, Igor I. Rybkin, A. I. Spira, G. J. Riely, K. P. Papadopoulos, J. K. Sabari, M. L. Johnson, R. S. Heist, L. Bazhenova, M. Barve, J. M. Pacheco, T. A. Leal, K. Velastegui, C. Cornelius, P. Olson, J. G. Christensen, T. Kheoh, R. C. Chao, and S. H.I. Ou
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation, Melissa L. Johnson, Sai-Hong Ignatius Ou, Minal Barve, Igor I. Rybkin, Kyriakos P. Papadopoulos, Ticiana A. Leal, Karen Velastegui, James G. Christensen, Thian Kheoh, Richard C. Chao, and Jared Weiss
Clinical outcomes of patient migration in locally advanced rectal cancer from community cancer centers: An analysis of the National Cancer Database, R. Kumar, S. Bhandari, P. Ngo, Sukhpreet RK Singh, S. J. Malapati, and A. Rojan
Progressive hyperleukocytosis associates with differential syndrome in acute promyelocytic leukemia patients treated with all-trans retinoic acid and arsenic trioxide, Qunfang Li and Yue Guo
4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC, J. Mazieres, A. Rittmeyer, Shirish M. Gadgeel, T. Hida, D. Gandara, D. Cortinovis, F. Barlesi, W. Yu, C. Matheny, M. Ballinger, and K. Park
KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC), R. McDermott, J. N. Graff, E. S. Antonarakis, C. J. Hoimes, S. T. Tagawa, Clara Hwang, D. Kilari, A. JT Tije, A. Omlin, U. N. Vaishampayan, A. Elliott, H. Wu, J. Kim, C. Schloss, and J. S. De Bono
Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC), D. Y. Oh, T. Arkenau, K. W. Lee, M. Alsina, F. M. Marti, I. J. Chung, W. Saif, Ding Wang, P. O'Dwyer, I. Chau, M. A. Lee, E. Chong, J. Hilger-Rolfe, G. Cole, and S. Y. Kim
KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update, A. G. Omlin, J. N. Graff, C. J. Hoimes, S. T. Tagawa, Clara Hwang, D. Kilari, A. J. Ten Tije, R. McDermott, U. N. Vaishampayan, T. Elliott, W. R. Gerritsen, H. Wu, J. Kim, C. Schloss, J. S. de Bono, and E. S. Antonarakis
Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression, S. I. Ou, B. Solomon, A. Shaw, Shirish M. Gadgeel, B. Besse, R. A. Soo, A. Abbattista, H. Thurm, F. Toffalorio, R. J. Wiltshire, and A. Bearz
Tissue sound speed is more strongly associated with breast cancer risk than mammographic percent density: A comparative case-control study, M. Sak, N. Duric, R. Pfeiffer, M. Sherman, P. Littrup, M. Simon, D. Gorski, T. Albrecht, Haythem Y. Ali, R. Brem, S. Fan, and G. Gierach
Magnetic Resonance Guided Stereotactic Ablative Radiation Therapy Versus External Beam RT with Chemotherapy For Pancreatic Cancer: Single Institution Toxicity Analysis Of Patients Treated In An Urban Academic Center, Eric Schaff, Kendyll J. Gartrelle, Celina Kirsch, Farzan Siddiqui, Munther Ajlouni, Jadranka Dragovic, Ibrahim Aref, Mira M. Shah, David Kwon, Irina Dobrosotskaya, Rupen Shah, Gazala Khan, and Parag J. Parikh
A Phase 1b/2a Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Nanogenistein in Combination with Chemoradiotherapy for Non-small Cell Lung Cancer, C B. Simone, Benjamin Movsas, E. M. Gore, P Mohindra, Z Vujaskovic, Ding Wang, Munther Ajlouni, S Menon, J Thompson, Stephen L. Brown, M Kurman, J C. Dykstra, L Rillo, M Ingram, A Serebrenik, and M D. Kaytor
Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours, L. L. Siu, Ding Wang, J. Hilton, R. Geva, D. Rasco, A. K. Abraham, J. F. Markensohn, L. Suttner, S. Siddiqi, R. A. Altura, and C. Maurice-Dror
Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199, U. N. Vaishampayan, T. Elliott, A. G. Omlin, J. N. Graff, C. J. Hoimes, S. T. Tagawa, Clara Hwang, D. Kilari, A. J. T Tije, R. S. McDermott, W. R. Gerritsen, H. Wu, J. Kim, S. Schloss, J. S. de Bono, and E. S. Antonarakis
Submissions from 2019
A differential response to cetuximab in patients with recurrent unresectable or metastatic head and neck cancer following immunotherapy (IO) exposure: An institutional experience, Haythem Ali, Z. A. Rahman, and Jawad Sheqwara
Evaluation of Tumor Heterogeneity in Prostate Biopsy Samples, Pavithra D. Arachchige, Shannon Carskadon, Gaury Dhamdhere, Mireya Diaz-Insua, R. Craig, James O. Peabody, Madhu P. Menon, Sean R. Williamson, Nilesh S. Gupta, and Nallasivam Palanisamy
Four vs six cycles of docetaxel and cyclophosphamide (TC) in early stage triple-negative breast cancer, Aparna Basu, Hadi Mohammed, Sharmeen Mahmood, Vrushali Dabak, and Randa Loutfi
Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC), J. E. Bauman, J. Harris, R. Uppaluri, M. Yao, R. L. Ferris, J. Chen, R. C. Jordan, N. P. Joshi, S. Jujjuvaparu, D. Blakaj, M. Razaq, Jawad Sheqwara, L. K. Mell, N. Sen, D. A. Clump, M. Garg, E. Yilmaz, and Q. T. Le
Antitumor Activity of Pembrolizumab Plus Dinaciclib in Patients with Diffuse Large B Cell Lymphoma: The Phase 1b KEYNOTE-155 Study, G. Gregory, P. Walker, D. Mahadevan, Ding Wang, J. Chang, F. Hernandez-Ilizaliturri, A. Klein, W. Rybka, N. Wagner-Johnson, C. Escobar, J. M. Pagel, A. Mohrbacher, S. Opat, J. Shortt, H. Ma, J. Gwo, M. Farooqui, and H. Quach
Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with Ravulizumab: Results of a 52-week extension from two phase 3 studies, Anita Hill, Caroline I. Piatek, Régis Peffault de Latour, Lily L.L. Wong, Richard A. Wells, Robert A. Brodsky, Jin Seok Kim, Junichi Nishimura, Philip Kuriakose, Rodrigo Pavani, Peng Liu, Stephan Ortiz, Hubert Schrezenmeier, Jong-Wook Lee, and Austin Kulasekararaj
Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy, C. L. Ho, D. S. Ettinger, P. N. Chen, H. Cheng, W. C. Wen, S. Y. Wu, T. M. Jahan, M. J. Fidler, B. W. Lash, Igor I. Rybkin, and N. Stanton
Tumors expressing ACKR1 exhibit a unique signature of tumor-infiltrating immune cells in women with breast cancer, Brittany D. Jenkins, T. Fleifel, Rachel Martini, Haythem Ali, Lisa A. Newman, and M. Davis
Predictive accuracy of the low erythropoietin level for the diagnosis of polycythemia vera, Oleksandra Lupak, Xiaoxia Han, Peter Xie, Sharmeen Mahmood, Hadi Mohammed, and Vijayalakshmi Donthireddy
Arctin and Arctigenin as a Potential Treatment for Solid Tumors, Mani Maheshwari, Joe Media, Q. Jia, and Frederick A. Valeriote
Outcomes of tbo-filgrastim, filgrastim-sndz or filgrastim for mobilization in patients undergoing an autologous hematopoietic stem cell transplant: A single center experience, Klodiana Neme, David R. Henkin, Nancy Mikulandric, Meredith Grycki, Alexander Michaels, Chadd Smith, and Josephine Emole
First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies, K. P. Papadopoulos, N. J. Lakhani, M. L. Johnson, H. Park, Ding Wang, T. A. Yap, A. Dowlati, R. G. Maki, F. Lynce, S. V. Ulahannan, K. Kelly, T. N. Sims, A. L. Bredlau, D. Bramble, A. G. Ortiz, M. Zhu, H. Chen, M. Karasarides, and G. Kroog
A study of REGN3767, an antiLAG3 antibody, alone and in combination with cemiplimab (REGN2810), an antiPD1 antibody in advanced cancers, K. P. Papadopoulos, N. Lakhani, M. L. Johnson, H. Park, Ding Wang, T. A. Yap, K. N. Moore, T. N. Sims, C. A. Emeremni, M. Karasarides, and G. S. Kroog
Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: Interim results of a patient survey of ravulizumab (ALXN1210) and eculizumab, J. Peipert, A. Kulasekararaj, F. Gonzalez-Fernandez, S. Yount, C. Martens, A. Sparling, K. Webster, D. Cella, S. Rottinghaus, B. Donato, I. Tomazos, A. Gaya Valls, L. Mitchell, A. Hill, R. Wells, C. Piatek, Philip Kuriakose, I. Murakhovskaya, S. Khaled, and K. Kaiser
2629 IV Iron in the Setting of Value-Based Care: Quality-of-Life Improvement and Perioperative Optimization of Anemia in The Gynecologic Population, Haleema Saeed, Sharmeen Mahmood, Marian R. Girgis, Ghadear Shukr, Philip Kuriakose, and Roopina Sangha
Fully integrated multi-disciplinary care in head and neck cancer: The Henry Ford Health System model, Amy M. Williams
Submissions from 2018
Utilization of the three Magee equations to select patients for genomic testing, Haythem Y. Ali, Zaid Abdel-Rahman, Laura Favazza, and Dhananjay A. Chitale
Evaluation of ERG as a biomarker of responsiveness in a randomized trial of enzalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer, S. R. Chinni, U. N. Vaishampayan, L. K. Heilbrun, L. Semaan, D. Smith, D. Modi, P. Monk, Sheela Tejwani, G. Sonpavde, K. Dobson, B. Dickow, E. Heath, J. Fontana, and M. L. Cher
Preparation and cytotoxicity evaluation of acetylated fijianolides (A.K.A. laulimalide), C. V. Cook, T. A. Johnson, D. Coppage, N. L. McIntosh, M. A. Ogarrio, K. Tenney, Frederick A. Valeriote, and P. Crews
Neoadjuvant phase II trial of chemo-radiotherapy (CRT) in patients with resectable (R) and borderline resectable (BR) pancreatic ductal adenocarcinoma (PDA), Vijay Damarla, Irina Dobrosotskaya, Farzan Siddiqui, Ira Wollner, Mohammad Raoufi, Jia Li, David Kwon, and Gazala Khan
Outcome of non-germinal center/activated b-cell type diffuse large b-cell lymphoma determined by ihc in a single institution over 7 years, Marian R. Girgis, Shatha Farhan, Nalini Janakiraman, and Edward Peres
Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer, R. Hassan, Ding Wang, J. Wrangle, A. Thomas, A. Byars, L. Asschert, R. Atienza, P. Rajagopalan, A. Walter, J. Zhang, N. Sarapa, and H. Kindler
